Lakefront Biotherapeutics stock

LKFT · Euronext Amsterdam · EUR

Compare Lakefront Biotherapeutics
€31.46Change from previous close: +0.77%Absolute change: +€0.24

Close · November 17, 2026

Price history

+19.83% over the period

1 year: from €26.62 (November 17, 2025) to €31.90 (November 17, 2026), +19.83%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026€31.90
October 30, 2026€28.92
September 30, 2026€26.42
August 31, 2026€24.56
July 31, 2026€23.86
June 30, 2026€26.22
May 29, 2026€24.46
April 30, 2026€24.14
March 31, 2026€26.18
February 27, 2026€28.42
January 30, 2026€28.44
December 31, 2025€28.00
November 28, 2025€27.04
November 17, 2025€26.62

At a glance

  • The company

    Biotechnology company developing oncology and immunology medicines including CAR-T cell therapies and other pipeline candidates

  • Latest results

    Quarter to June 30, 2026 · EPS €0.03 (estimate -€0.60)

TickerLandia's take on Lakefront Biotherapeutics

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€22.32
52-wk high€32.00

−1.69% from the 52-week high

Analysts · 8 analysts

Average target€31.46−0.01% vs. price

Buy 1 · Hold 5 · Sell 2 · Hold

TickerLandia Fingerprint: Lakefront Biotherapeutics

Compared with similar companies: very low price, very high financial strength, and very strong momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Lakefront Biotherapeutics is cheaper than similar companies

Lakefront Biotherapeutics's P/E (trailing 12 months): 3.21, −81% against the median of a group of 9 similar companies (17.2).

Compared with 9 similar companies

Lakefront Biotherapeutics's metrics compared with similar companies
MetricLakefront BiotherapeuticsPosition in the groupBand
P/E (trailing 12 months)3.21Low
Operating margin57.5%High
ROE20.1%Middle
Debt/equity0.00Low
Price/book0.61Low

Grey band: the middle half of the group; tick: the median; dot: Lakefront Biotherapeutics. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€12.11M

Latest quarter · Q2 2026

Net income

€2.11M

Latest quarter · Q2 2026

Quarterly net margin

17.4%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€1.99B
P/E
3.2
EPS
€9.40
Volume
63.83K
Daily trading
€2.63M
Dividend yield
0.00%

How Lakefront Biotherapeutics is changing

All results
  • Revenue grew 18.4% a year on average over the last 5 years

  • Operating margin rose from −54.3% to 48.1%

  • Profitable in 3 of 5 fiscal years

Returns

Lakefront Biotherapeutics returns

€1,000 invested in Lakefront Biotherapeutics 5 years ago, on November 17, 2021, would be worth €723 today: −27.66% in total, −6.27% per year. This is the price return only: dividends are excluded.

PeriodLakefront BiotherapeuticsAEX€1,000 becomes
1 month+20.56%−1.74%€1,206
6 months+34.44%+10.99%€1,344
Year to date+13.93%+17.89%€1,139
1 year+19.83%+18.63%€1,198
3 years−7.40%+47.84%€926
5 years−27.66%+35.51%€723
10 years−44.72%+148.21%€553

Over the last 6 months it has done better than 56% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Lakefront Biotherapeutics: technical analysis

Lakefront Biotherapeutics is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 87.4% below its all-time closing high (€249.50, February 21, 2020).

Trend
Upward
RSI (14 sessions)
70
Between 30 and 70
vs 200-session average
+21.45%

Active signals

  • New 52-week high.

Support and resistance

Price areas where Lakefront Biotherapeutics has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price€31.46
  3. Support€29.68−5.66%4 touches, last on March 5, 2026
  4. Support€28.98−7.88%2 touches, last on March 18, 2026
  5. Support€27.76−11.75%5 touches, last on March 12, 2026

Volatility and risk

Over the last year it has moved little with the AEX.

Beta (1 year) vs AEX
0.36
Volatility (60 sessions, annualised)
29.9%
Largest fall in the last year
−23.95%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Lakefront Biotherapeutics: seasonality

Average monthly price change over 22 years

+1.8%Jan−2.0%Feb+0.5%Mar+2.4%Apr+2.8%May−3.1%Jun+2.5%Jul−1.6%Aug−0.7%Sep−0.8%Oct+0.3%Nov+5.7%Dec

Over the last 22 years, the strongest month for Lakefront Biotherapeutics has been December: +5.74% on average, positive in 14 years out of 21. The weakest has been June: −3.15% on average, positive in 5 years out of 22. November, the current month, has been positive in 9 years out of 21 (+0.32% on average).

Show chart data
MonthAverageMedianPositive years
January+1.82%0.00%8 of 21
February−1.97%0.00%5 of 21
March+0.47%0.00%7 of 21
April+2.43%−0.53%5 of 21
May+2.78%0.00%8 of 21
June−3.15%−3.84%5 of 22
July+2.53%0.00%9 of 22
August−1.62%−0.13%6 of 22
September−0.73%0.00%7 of 22
October−0.77%−0.30%6 of 22
November+0.32%0.00%9 of 21
December+5.74%+7.56%14 of 21

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Lakefront Biotherapeutics and its competitors

With 196 employees, Lakefront Biotherapeutics NV develops medicines in oncology and immunology, with its activity centred mainly on the United States and Europe. Its clinical pipeline includes GLPG3667, in a phase 2 trial for dermatomyositis and systemic lupus erythematosus, and two CAR-T candidates manufactured at the point of care: GLPG5101, in a phase 1/2 trial for relapsed or refractory non-Hodgkin lymphoma, and GLPG5301, in phase 1/2 for relapsed or refractory multiple myeloma. The company also holds collaboration agreements with Gilead Sciences, Inc.

Headquarters
Mechelen, Belgium
Employees
196
Founded
1999
Chief executive
Henry Gosebruch
Lakefront Biotherapeutics and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Lakefront BiotherapeuticsLKFT$2.19B57.5%3.21+34.44%
Zealand PharmaZEAL$2.36B59.0%5.49−26.08%
Bavarian NordicBAVA$2.64B6.9%12.4+27.99%
BioArcticBIOA.B$2.72B19.6%262.7−6.04%
Pharma MarPHM$1.23B21.3%16.6−33.28%
IdorsiaIDIA$1.25B-68.4%—−10.71%

Same industry or related industries, similar size. Compare Lakefront Biotherapeutics with its competitors · Full profile